Haemonetics Co. (NYSE:HAE) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Haemonetics Co. (NYSE:HAE) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $101.22.

A number of research firms have recently weighed in on HAE. JMP Securities reduced their price target on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research note on Friday, February 7th. Raymond James restated a “strong-buy” rating and issued a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. Barrington Research dropped their price target on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Finally, Bank of America lowered Haemonetics from a “neutral” rating to an “underperform” rating and reduced their price objective for the stock from $95.00 to $68.00 in a research report on Friday, February 7th.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $60.80 on Monday. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The company has a market cap of $3.05 billion, a PE ratio of 23.94, a price-to-earnings-growth ratio of 1.11 and a beta of 0.41. The company has a 50 day moving average of $65.01 and a 200-day moving average of $74.25. Haemonetics has a 1-year low of $58.80 and a 1-year high of $97.97.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, equities research analysts forecast that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

A number of hedge funds have recently made changes to their positions in HAE. BNP Paribas Financial Markets increased its position in Haemonetics by 174.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier’s stock valued at $1,362,000 after purchasing an additional 10,774 shares during the period. Boston Trust Walden Corp boosted its stake in shares of Haemonetics by 13.1% in the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock valued at $71,500,000 after purchasing an additional 106,114 shares during the last quarter. FMR LLC increased its position in shares of Haemonetics by 206.3% during the third quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock worth $62,257,000 after buying an additional 521,640 shares during the period. Empowered Funds LLC bought a new position in Haemonetics during the fourth quarter worth $319,000. Finally, Pacer Advisors Inc. lifted its holdings in Haemonetics by 36.1% in the fourth quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier’s stock valued at $789,000 after buying an additional 2,680 shares during the period. 99.67% of the stock is currently owned by institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.